Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 1.69% is 135% above its 5-year average of -4.78%, near the high end of its 5-year range (-13.18%–1.69%).
146.75% above its 12-month average of -3.62%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 3.93%.
RETURN ON ASSETS (ROA)
1.69%
RETURN ON ASSETS (ROA) AVG TTM
-3.62%
RETURN ON ASSETS (ROA) AVG 3Y
-6.49%
RETURN ON ASSETS (ROA) AVG 5Y
-4.78%
RETURN ON ASSETS (ROA) AVG 10Y
-2.66%
RETURN ON ASSETS (ROA) AVG 15Y
-2.24%
RETURN ON ASSETS (ROA) AVG 20Y
-1.00%
CURRENT VS TTM AVG
+146.75%
CURRENT VS 3Y AVG
+126.03%
CURRENT VS 5Y AVG
+135.36%
CURRENT VS 10Y AVG
+163.58%
CURRENT VS 15Y AVG
+175.57%
CURRENT VS 20Y AVG
+269.45%
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+105.24%
vs the sector median at left
ImmuCell Corporation
Market Cap
$90.20M
Return on Assets (ROA)
1.69%
TTM Avg
-3.62%
3Y Avg
-6.49%
5Y Avg
-4.78%
Market Cap
$90.37M
Return on Assets (ROA)
-88.24%
TTM Avg
-139.34%
3Y Avg
-100.15%
5Y Avg
-71.92%
Market Cap
$89.78M
Return on Assets (ROA)
-30.70%
TTM Avg
-50.88%
3Y Avg
-51.94%
5Y Avg
-48.05%
Market Cap
$90.64M
Return on Assets (ROA)
46.45%
TTM Avg
-49.63%
3Y Avg
-50.17%
5Y Avg
-40.85%
Market Cap
$89.44M
Return on Assets (ROA)
-86.56%
TTM Avg
-66.44%
3Y Avg
-84.84%
5Y Avg
-75.69%
Market Cap
$87.96M
Return on Assets (ROA)
8.52%
TTM Avg
11.64%
3Y Avg
-8.81%
5Y Avg
-6.61%
Market Cap
$87.85M
Return on Assets (ROA)
-79.38%
TTM Avg
41.63%
3Y Avg
-36.06%
5Y Avg
-44.84%
Market Cap
$87.27M
Return on Assets (ROA)
-169.86%
TTM Avg
-100.47%
3Y Avg
-69.80%
5Y Avg
-64.10%
Market Cap
$93.96M
Return on Assets (ROA)
-1.90%
TTM Avg
1.32%
3Y Avg
1.93%
5Y Avg
1.93%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ImmuCell Corporation (ICCC) | $90.20M | 1.69% | -3.62% | -6.49% | -4.78% |
| Biomea Fusion, Inc. (BMEA)vs › | $90.37M | -88.24% | -139.34% | -100.15% | -71.92% |
| Equillium, Inc. (EQ)vs › | $89.78M | -30.70% | -50.88% | -51.94% | -48.05% |
| Rallybio Corporation (RLYB)vs › | $90.64M | 46.45% | -49.63% | -50.17% | -40.85% |
| electroCore, Inc. (ECOR)vs › | $89.44M | -86.56% | -66.44% | -84.84% | -75.69% |
| CareCloud, Inc. (CCLD)vs › | $87.96M | 8.52% | 11.64% | -8.81% | -6.61% |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $87.85M | -79.38% | 41.63% | -36.06% | -44.84% |
| Neumora Therapeutics, Inc. Common Stock (NMRA)vs › | $87.27M | -169.86% | -100.47% | -69.80% | -64.10% |
| Park Dental Partners, Inc. Common Stock (PARK)vs › | $93.96M | -1.90% | 1.32% | 1.93% | 1.93% |
| PMV Pharmaceuticals, Inc. (PMVP)vs › | $85.86M | -91.66% | -48.70% | -37.97% | -29.79% |
ROA
1.7%
ROE
2.5%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -2.45% |
| 2024-12-31 | -4.78% |
| 2023-12-31 | -13.18% |
| 2022-12-31 | -5.56% |
| 2021-12-31 | -0.18% |
| 2020-12-31 | -2.53% |
| 2019-12-31 | -3.35% |
| 2018-12-31 | -7.09% |
| 2017-12-31 | -0.49% |
| 2016-12-31 | 2.06% |
| 2015-12-31 | 8.31% |
| 2014-12-31 | -1.51% |
| 2013-12-31 | 1.07% |
| 2012-12-31 | 0.81% |
| 2011-12-31 | -3.73% |
| 2010-12-31 | -3.58% |
| 2009-12-31 | -2.17% |
| 2008-12-31 | -4.63% |
| 2007-12-31 | 6.36% |
| 2006-12-31 | 5.69% |
| 2005-12-31 | 7.11% |
| 2004-12-31 | 1.51% |
| 2003-12-31 | 5.02% |
| 2002-12-31 | 11.80% |
| 2001-12-31 | 5.90% |
| 2000-12-31 | 34.48% |
| 1999-12-31 | 14.29% |
| 1998-12-31 | -3.23% |
| 1997-12-31 | 9.38% |
| 1996-12-31 | -3.23% |
